Thursday, January 20, 2022

Oral Immunotherapy Induces Remission of Peanut Allergy in Some Young Children

The youngest children and those who started the trial with lower levels of peanut-specific antibodies were most likely to achieve remission.
NIH/NIAID Template Banner

Thursday, January 20, 2022

Oral Immunotherapy Induces Remission of Peanut Allergy in Some Young Children

Peanuts in a bowl

Giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth, a NIAID-funded clinical trial has found. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years. Remission was defined as being able to eat 5 grams of peanut protein, equivalent to 1.5 tablespoons of peanut butter, without having an allergic reaction six months after completing immunotherapy. The youngest children and those who started the trial with lower levels of peanut-specific antibodies were most likely to achieve remission. The results of the trial, called IMPACT, were published today in the journal The Lancet.

Read More


This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107 GovDelivery logo

No comments:

Post a Comment

Invitation: Join Fausto Pugliese's Stock Trading Class

It's a fantastic opportunity to gain valuable insights and practical techniques to enhance your trading skills. ...